These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9681662)

  • 1. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
    De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
    Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue and interspecies comparison of catechol-
    Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
    Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
    Vieira-Coelho MA; Soares-da-Silva P
    Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
    J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA; Soares-da-Silva P
    Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC; Lambert JD
    Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S; Gordin A; Männistö PT
    Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
    Detrait ER; Carr GV; Weinberger DR; Lamberty Y
    Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
    Korlipara LV; Cooper JM; Schapira AH
    Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M; Ukai W; Ozawa H; Riederer P
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT
    Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906
    [No Abstract]   [Full Text] [Related]  

  • 14. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
    J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats.
    Khromova I; Voronina T; Kraineva VA; Zolotov N; Männistö PT
    Behav Brain Res; 1997 Jun; 86(1):49-57. PubMed ID: 9105581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
    Forsberg MM; Huotari M; Savolainen J; Männistö PT
    Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
    Lv X; Wang XX; Hou J; Fang ZZ; Wu JJ; Cao YF; Liu SW; Ge GB; Yang L
    Toxicol Appl Pharmacol; 2016 Jun; 301():42-9. PubMed ID: 27089846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.